Global Statistics on Uterine Cancer

• Uterine cancer statistics provide essential insights into global disease burden and population risk.
• There is substantial geographic variation in incidence, with higher diagnosis rates in high-income settings.
• Age is among the most important risk factors, with most cases occurring in postmenopausal individuals.
• Outcomes depend largely on how early the disease is detected and whether effective treatment is available quickly.
• Global data highlight the importance of prevention strategies and equitable healthcare access.

Uterine Cancer Statistics Worldwide

Globally, uterine cancer remains a notable health concern, and incidence rates vary widely by region. Uterine cancer statistics worldwide show that the disease is more commonly diagnosed in high-income countries, particularly in North America and parts of Europe. Factors such as longer life expectancy, higher obesity prevalence, and better access to diagnostic services contribute to these trends. Conversely, lower-income regions often show fewer diagnosed cases but higher death rates, largely driven by late diagnosis and limited access to care. Global statistics show changing incidence over recent decades, underscoring the need for increased public awareness and timely evaluation of symptoms. Because there is no routine screening test recommended for average-risk, symptom-free people for endometrial cancer, understanding worldwide patterns can help identify disparities in care and improve cancer control strategies.

According to the World Health Organization (WHO) and GLOBOCAN, uterine cancer remains one of the leading gynecologic cancers globally, with hundreds of thousands of new cases diagnosed each year. These sources stress that prompt diagnosis and fair access to healthcare are fundamental to better outcomes.

Uterine Cancer Prevalence and Global Burden

Uterine cancer prevalence refers to the number of women living with the disease at a given time. Prevalence reflects both incidence and survival, offering a broader picture of overall disease burden. In regions with effective early detection and treatment, prevalence may be higher because more patients live longer after diagnosis. The burden of uterine cancer extends beyond clinical outcomes, affecting healthcare systems, economies, and quality of life.

Many survivors need long-term follow-up and supportive services, such as help managing menopausal symptoms after surgery, sexual health concerns, or (in some cases) lymphedema risk. Understanding prevalence data helps health systems allocate resources, plan survivorship care, and develop targeted interventions to reduce long-term impact.

Uterine Cancer Statistics by Age

Age is a critical factor in uterine cancer epidemiology. Uterine cancer statistics by age consistently show that the disease primarily affects postmenopausal women. Incidence rates increase significantly after the age of 50, with the highest rates observed among women aged 60 and older. However, recent data indicate a gradual rise in diagnoses among younger age groups in some countries. Hormonal factors, obesity, metabolic conditions, and genetic predisposition may contribute to earlier onset. Age-based statistics guide screening recommendations and risk assessment strategies. Identifying age-related patterns enables clinicians to tailor prevention efforts and reinforces the importance of symptom awareness across different life stages.

Global Uterine Cancer Incidence by Age Group

According to US SEER 21 (2018–2022) — “Percent of new cases by age group”:

Age group	Numeric estimate (share of new cases)	Clinical significance (patient-friendly)
<45	~7.3% (<20 + 20–34 + 35–44)	Less common; if diagnosed young, clinicians may consider hereditary risk in the right context
45–54	13.7%	Risk rises; symptom awareness and timely evaluation matter
55–64	32.0%	Most common age range for diagnosis in this dataset
65+	~47.0% (65–74 + 75–84 + >84)	Highest overall caseshare; often more healthcare utilization

Uterine Cancer Demographics

Uterine cancer demographics show differences in incidence and outcomes across populations by ethnicity, socioeconomic status, and geography. These differences are influenced by multiple factors, including stage at diagnosis, access to timely and high-quality treatment, and differences in tumor subtype distribution across groups.

Some communities face barriers to care that can delay evaluation and diagnosis, increasing the likelihood of advanced disease at presentation. Demographic data also reflect variation in risk factors such as obesity and reproductive history, as well as differences in access to preventive and follow-up care. Understanding these patterns supports fair healthcare policy, culturally responsive education, and targeted public health efforts to improve timely referral and treatment.

Uterine Cancer Survival Statistics

Outcomes for uterine cancer differ substantially depending on how early it is detected and whether effective treatment is available. Uterine cancer survival statistics demonstrate that early-stage disease is associated with favorable outcomes, often exceeding 80 percent at five years. Advanced-stage disease is associated with lower survival because it is more difficult to treat, has spread beyond the uterus, and is more likely to recur. Survival data provide insights into treatment outcomes and highlight the potential impact of earlier diagnosis. These statistics also help clinicians counsel patients regarding prognosis and guide research priorities aimed at improving outcomes for high-risk populations.

Survival statistics also play a key role in evaluating progress in cancer treatment and early detection programs. Advances in surgical methods, radiation therapy, and systemic treatments have improved outcomes in many parts of the world. Continued research and international collaboration are still needed to further raise survival rates, especially for advanced-stage disease.

Average Age for Uterine Cancer Diagnosis

The average age for uterine cancer diagnosis is typically in the early 60s, aligning with postmenopausal hormonal changes. Most women are diagnosed after menopause, although individual risk factors can influence age at onset. Conditions such as obesity, diabetes, and prolonged estrogen exposure may influence risk and prompt earlier evaluation. Understanding age trends helps clinicians with risk stratification and supports symptom-awareness counseling and risk-based discussions. Public health strategies can use age-based data to target education and improve early symptom recognition among higher-risk groups.

Although the average age at diagnosis remains relatively stable, shifts in population health trends may influence future patterns. Rising obesity rates and metabolic disorders have been associated with increased uterine cancer risk, potentially affecting age distribution over time. Observing these patterns supports better-targeted prevention and earlier detection strategies.

FAQs About Uterine Cancer Statistics

How common is uterine cancer worldwide?

Uterine cancer is a leading gynecologic malignancy diagnosed around the world. Incidence rates vary by region, with higher rates reported in developed countries due to longer life expectancy and improved diagnostic practices. Global cancer databases estimate hundreds of thousands of new cases each year, emphasizing the growing public health impact of the disease.

Does age significantly affect uterine cancer risk?

Yes, age is one of the strongest risk factors. Most cases are diagnosed in postmenopausal women, typically in their 60s. Even so, the disease can occur in younger women, particularly those with certain risk factors. Any bleeding after menopause should be checked by a healthcare professional. Age-based trends are useful for shaping symptom awareness and clinical evaluation.

Why do uterine cancer statistics differ between countries?

Differences in healthcare access, cancer registry systems, lifestyle factors, and population demographics all influence reported statistics. Countries with comprehensive diagnosis and registry reporting systems tend to document higher incidence and may achieve better survival outcomes through earlier evaluation and timely treatment.